Wave Life Sciences Q3 revenue jumps, beats estimates

What happened

Wave Life Sciences said third-quarter revenue beat analyst estimates. The revenue increase was mainly due to a $12 mln milestone payment from GSK for candidate selection. The company reported smaller-than-expected pretax and net loss figures.

Confirmed

Global impact / market context

Higher revenue and a smaller loss mean Wave uses less cash to keep operating, which matters because drug research is expensive. The GSK payment shows a partner pays for progress, and Wave expects cash to fund operations into the third quarter of 2028.

Analyst inference

Analysts rate the shares buy on average, with 18 strong buy or buy ratings and one hold. That suggests investors expect the pipeline to deliver. Still, the company spends heavily on research, so future results depend on trials like WVE-006 and WVE-007 succeeding.

Analyst inference

What to watch

1. Wave plans to start a registrational trial for WVE-006 in AATD, with an interim analysis for accelerated approval. A registrational trial is a late-stage study meant to support regulatory approval. Confirmed
2. Wave plans to begin a post-incretin maintenance trial for WVE-007 in the fourth quarter of 2026. Investors should watch whether that start date holds and whether the trial design is disclosed. Proposed
3. Watch research and development spending, which rose as Wave advanced WVE-006 and WVE-007. Higher spending can shorten the cash runway that Wave says lasts into the third quarter of 2028. Analyst inference

Evidence

• Original source link unavailable